Blood cadmium levels as a marker for early lung cancer detection.


Journal

Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS)
ISSN: 1878-3252
Titre abrégé: J Trace Elem Med Biol
Pays: Germany
ID NLM: 9508274

Informations de publication

Date de publication:
Mar 2021
Historique:
received: 22 06 2020
revised: 16 09 2020
accepted: 06 11 2020
pubmed: 30 11 2020
medline: 29 9 2021
entrez: 29 11 2020
Statut: ppublish

Résumé

We assessed whether blood cadmium levels were associated with incident lung cancer and could be used in the context of a screening program for early-stage lung cancer. We measured blood cadmium levels among 205 lung cancer patients and 205 matched controls. Cases and controls were matched for sex, age and smoking history (total pack-years, years since cessation for former smokers). The odds ratio for those in the highest quartile of cadmium level (versus lowest) was four-fold (OR = 4.41, 95 % CI:2.01-9.67, p < 0.01). The association was present in former smokers (OR = 16.8, 95 % CI:3.96-71.2, p < 0.01), but not in current smokers (OR = 1.23, 95 % CI: 0.34-4.38) or in never smokers (OR not defined). Among former smokers, the association was present in both early- and late-stage lung cancer. Blood cadmium levels may be a marker to help with the early detection of lung cancer among former smokers.

Sections du résumé

BACKGROUND BACKGROUND
We assessed whether blood cadmium levels were associated with incident lung cancer and could be used in the context of a screening program for early-stage lung cancer.
MATERIAL AND METHODS METHODS
We measured blood cadmium levels among 205 lung cancer patients and 205 matched controls. Cases and controls were matched for sex, age and smoking history (total pack-years, years since cessation for former smokers).
RESULTS RESULTS
The odds ratio for those in the highest quartile of cadmium level (versus lowest) was four-fold (OR = 4.41, 95 % CI:2.01-9.67, p < 0.01). The association was present in former smokers (OR = 16.8, 95 % CI:3.96-71.2, p < 0.01), but not in current smokers (OR = 1.23, 95 % CI: 0.34-4.38) or in never smokers (OR not defined). Among former smokers, the association was present in both early- and late-stage lung cancer.
CONCLUSION CONCLUSIONS
Blood cadmium levels may be a marker to help with the early detection of lung cancer among former smokers.

Identifiants

pubmed: 33249371
pii: S0946-672X(20)30247-9
doi: 10.1016/j.jtemb.2020.126682
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Cadmium 00BH33GNGH

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

126682

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier GmbH.. All rights reserved.

Auteurs

Marcin R Lener (MR)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Edyta Reszka (E)

Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, ul.św. Teresy od Dzieciątka Jezus 8, 91-348 Łódź, Poland.

Wojciech Marciniak (W)

Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland.

Monika Lesicka (M)

Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, ul.św. Teresy od Dzieciątka Jezus 8, 91-348 Łódź, Poland.

Piotr Baszuk (P)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Ewa Jabłońska (E)

Department of Molecular Genetics and Epigenetics, Nofer Institute of Occupational Medicine, ul.św. Teresy od Dzieciątka Jezus 8, 91-348 Łódź, Poland.

Katarzyna Białkowska (K)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Magdalena Muszyńska (M)

Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland.

Sandra Pietrzak (S)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Róża Derkacz (R)

Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland.

Tomasz Grodzki (T)

Department of Thoracic Surgery and Transplantation, Pomeranian Medical University in Szczecin, ul. A. Sokołowskiego 11, 70-891 Szczecin, Poland.

Janusz Wójcik (J)

Department of Thoracic Surgery and Transplantation, Pomeranian Medical University in Szczecin, ul. A. Sokołowskiego 11, 70-891 Szczecin, Poland.

Małgorzata Wojtyś (M)

Department of Thoracic Surgery and Transplantation, Pomeranian Medical University in Szczecin, ul. A. Sokołowskiego 11, 70-891 Szczecin, Poland.

Tadeusz Dębniak (T)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Cezary Cybulski (C)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland.

Jacek Gronwald (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland.

Bartosz Kubisa (B)

Department of Thoracic Surgery and Transplantation, Pomeranian Medical University in Szczecin, ul. A. Sokołowskiego 11, 70-891 Szczecin, Poland.

Jarosław Pieróg (J)

Department of Thoracic Surgery and Transplantation, Pomeranian Medical University in Szczecin, ul. A. Sokołowskiego 11, 70-891 Szczecin, Poland.

Piotr Waloszczyk (P)

Independent Laboratory of Pathology, Zdunomed, ul. Energetyków 2, 70-656 Szczecin, Poland.

Rodney J Scott (RJ)

Medical Genetics, Hunter Medical Research Institute, Priority Research Centre for Cancer Research, Innovation and Translation, School of Biomedical Sciences and Pharmacy, Faculty of Health and Medicine, University of Newcastle, Pathology North, John Hunter Hospital, Cnr King and Auckland Streets, Newcastle NSW 2300 Australia.

Anna Jakubowska (A)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland.

Steven A Narod (SA)

Women's College Research Institute, Toronto, Ontario, Canada; Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.

Jan Lubiński (J)

Department of Genetics and Pathology, International Hereditary Cancer Center, Pomeranian Medical University in Szczecin, ul. Unii Lubelskiej 1, 71-252 Szczecin, Poland; Read-Gene, Grzepnica, ul. Alabastrowa 8, 72-003 Dobra (Szczecińska), Poland. Electronic address: lubinski@pum.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH